Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Kentucky
  • Louisville


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Transcutaneous Spinal Stimulation: Safety and Feasibility for Trunk Control in Children With Spinal Cord Injury
    NCT03975634
    Condition:   Spinal Cord Injuries
    Intervention:   Device: Transcutaneous Spinal Stimulation
    Sponsors:   University of Louisville;   National Center of Neuromodulation for Rehabilitation (NM4R)
    Recruiting
  • Conquering Feared Foods Study
    NCT04155788
    Conditions:   Eating Disorder Symptom;   Fear
    Intervention:   Behavioral: Food Exposure
    Sponsor:   University of Louisville
    Recruiting
  • Adrenergic Cholinergic Enteric Measures/Mapping
    NCT04013282
    Condition:   Obesity
    Intervention:  
    Sponsor:   University of Louisville
    Recruiting
  • Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
    NCT03673462
    Condition:   Healthy Volunteers (Meningococcal Infection)
    Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
    NCT03636906
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
    NCT03691610
    Condition:   Healthy Volunteers (Meningococcal Infection)
    Interventions:   Biological: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine;   Biological: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine;   Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine;   Biological: Haemophilus b Conjugate Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine, Live, Oral, Pentavalent;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine Live;   Biological: Varicella Virus Vaccine Live
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
    NCT03537508
    Condition:   Meningococcal Infections
    Interventions:   Biological: MenACYW conjugate vaccine;   Biological: MenACYW-135 conjugate vaccine;   Biological: DTaP-IPV//Hib vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Pentavalent rotavirus vaccine;   Biological: Hepatitis B vaccine;   Biological: Measles, mumps, rubella (MMR) vaccine;   Biological: Varicella vaccine;   Biological: Hepatitis A vaccine
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Dextromethorphan Pediatric Acute Cough Study
    NCT02651116
    Condition:   Cough
    Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
    Sponsor:   Pfizer
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
    NCT03709680
    Conditions:   Solid Tumors;   Ewing Sarcoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Neuroblastoma;   Medulloblastoma;   Diffuse Intrinsic Pontine Glioma
    Interventions:   Drug: Palbociclib;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Pfizer
    Recruiting
  • A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
    NCT03725007
    Condition:   Juvenile Idiopathic Arthritis (JIA)
    Intervention:   Drug: Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
    NCT03988439
    Condition:   Psoriasis
    Intervention:   Drug: IDP-118 Lotion
    Sponsor:   Bausch Health Americas, Inc.
    Recruiting
  • Asymptomatic Congenital CMV Treatment
    NCT03301415
    Condition:   Congenital Cytomegalovirus Infection
    Intervention:   Drug: Valganciclovir
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
    NCT02891915
    Condition:   Pneumonia
    Interventions:   Drug: Amoxicillin;   Drug: Amoxicillin-clavulanate;   Drug: Cefdinir;   Other: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Study of Pediatric Migraine: The Pediatric Migraine Registry
    NCT03742024
    Condition:   Migraine
    Intervention:  
    Sponsors:   Duke University;   University of California, San Francisco
    Recruiting
  • Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
    NCT04074928
    Condition:   Influenza, Human
    Interventions:   Biological: QIVc;   Biological: Comparator QIV
    Sponsor:   Seqirus
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants
    NCT03979313
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Placebo
    Sponsor:   MedImmune LLC
    Recruiting
  • A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
    NCT03959488
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: MEDI8897;   Drug: Palivizumab
    Sponsor:   MedImmune LLC
    Recruiting
  • JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
    NCT03796676
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
    Sponsor:   Pfizer
    Recruiting
  • OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
    NCT03747458
    Condition:   Bilateral Nasal Polyposis
    Intervention:   Drug: OPN-375
    Sponsor:   Optinose US Inc.
    Recruiting
  • Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
    NCT02527681
    Condition:   Bacterial Infections
    Intervention:   Drug: ceftobiprole
    Sponsor:   Basilea Pharmaceutica
    Recruiting
  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
    NCT03429543
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Stress Hydrocortisone In Pediatric Septic Shock
    NCT03401398
    Condition:   Septic Shock
    Interventions:   Drug: Hydrocortisone, sodium succinate;   Drug: Normal saline
    Sponsors:   Jerry Zimmerman;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Canadian Institutes of Health Research (CIHR);   Canadian Critical Care Trials Group;   Children's Hospital of Eastern Ontario
    Recruiting
  • Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
    NCT03275922
    Condition:   Migraine
    Interventions:   Drug: Placebo ZNS;   Drug: ZNS
    Sponsors:   Impax Laboratories, LLC;   AstraZeneca
    Recruiting
  • Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission
    NCT03223753
    Condition:   Acute Lymphoblastic Leukemia in Remission
    Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
    NCT02875314
    Conditions:   Medulloblastoma;   Central Nervous System Embryonal Tumors
    Interventions:   Drug: Induction;   Drug: Single Cycle Intensive Chemotherapy;   Drug: Tandem 3 Cycle Intensive Chemotherapy
    Sponsors:   Nationwide Children's Hospital;   Children's Hospital Los Angeles
    Recruiting
  • National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
    NCT02852031
    Condition:   Hypoplastic Left Heart Syndrome (HLHS)
    Intervention:   Other: Collaborative Learning Network
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
    NCT02678312
    Condition:   Pediatric Heart Failure
    Interventions:   Drug: LCZ696;   Drug: Enalapril;   Drug: Placebo of LCZ696;   Drug: Placebo of Enalapril
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
    NCT02369653
    Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
    NCT03627767
    Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
    NCT03595124
    Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia.
    NCT03813407
    Condition:   Hyperkalaemia
    Interventions:   Drug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level;   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
    Sponsor:   AstraZeneca
    Recruiting
  • Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
    NCT03268421
    Conditions:   Fibromyalgia;   Myofascial Pain Syndrome;   Muscular Diseases;   Musculoskeletal Disease;   Rheumatic Diseases
    Interventions:   Behavioral: Fibromyalgia Integrative Training for Teens;   Behavioral: Cognitive Behavioral Therapy;   Behavioral: Graded Aerobic Exercise
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting
  • Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
    NCT02392078
    Conditions:   Metastatic Brain Tumor;   Primary Brain Tumor;   Epileptic/Seizure Foci
    Intervention:   Device: NeuroBlate System
    Sponsor:   Monteris Medical
    Recruiting
  • A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
    NCT04075266
    Condition:   Multiple Sclerosis
    Intervention:   Drug: Ocrelizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PROSpect: Prone and Oscillation Pediatric Clinical Trial
    NCT03896763
    Condition:   Acute Respiratory Distress Syndrome in Children
    Intervention:   Other: Either supine or prone positioning and either CMV or HFOV
    Sponsors:   University of Pennsylvania;   National Heart, Lung, and Blood Institute (NHLBI);   Duke University;   University Medical Center Groningen;   Boston Children’s Hospital
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
    NCT03245840
    Condition:   Eosinophilic Esophagitis (EoE)
    Intervention:   Drug: Budesonide oral suspension
    Sponsor:   Shire
    Recruiting
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    NCT03233204
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection
    NCT03219164
    Conditions:   Pseudomonas Aeruginosa Respiratory Tract Infection;   Cystic Fibrosis
    Interventions:   Drug: AZLI;   Drug: Placebo
    Sponsor:   Gilead Sciences
    Recruiting
  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
    NCT03213704
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213665
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03210714
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
    NCT03057626
    Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
    NCT02927769
    Condition:   Hodgkin Disease
    Interventions:   Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
    Sponsors:   Bristol-Myers Squibb;   Seattle Genetics, Inc.
    Recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
    NCT02723994
    Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting
  • Neuroblastoma Maintenance Therapy Trial
    NCT02679144
    Condition:   Neuroblastoma
    Intervention:   Drug: Difluoromethylornithine (DFMO)
    Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
    NCT02559778
    Condition:   Neuroblastoma
    Interventions:   Drug: Ceritinib;   Drug: dasatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
    Sponsors:   Giselle Sholler;   Dell, Inc.;   Beat NB Cancer Foundation
    Recruiting
  • Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
    NCT02303431
    Conditions:   Deep Vein Thrombosis;   Venous Thromboembolism
    Interventions:   Drug: Edoxaban low dose;   Drug: Edoxaban high dose
    Sponsor:   Daiichi Sankyo, Inc.
    Recruiting
  • LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
    NCT02205762
    Condition:   Langerhans Cell Histiocytosis
    Interventions:   Drug: Prednisone;   Drug: Vinblastine;   Drug: mercaptopurine;   Drug: INDOMETHACIN;   Drug: Methotrexate;   Drug: Cytosine Arabinoside;   Drug: 2-chlorodeoxyadenosine;   Procedure: hematopoietic stem cell transplantation (RIC-HSCT);   Biological: Intravenous immunoglobulin
    Sponsors:   North American Consortium for Histiocytosis;   Histiocyte Society
    Recruiting
  • Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder
    NCT01707394
    Condition:   Thromboembolism
    Intervention:   Drug: Apixaban
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Evaluation of the Duration of Therapy for Thrombosis in Children
    NCT00687882
    Condition:   Venous Thrombosis
    Interventions:   Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
    Sponsors:   Johns Hopkins All Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Evaluation of the Use of Medical Scribes in VAMC Emergency Departments and Specialty Care Clinics
    NCT04154462
    Condition:   Medical Scribes
    Intervention:   Other: Scribes
    Sponsors:   VA Boston Healthcare System;   US Department of Veterans Affairs
    Recruiting
  • A Prospective Observational Study of TPIAT
    NCT03260387
    Conditions:   Pancreatitis, Chronic;   Pancreatectomy; Hyperglycemia;   Pancreatitis
    Intervention:   Procedure: TPIAT
    Sponsors:   University of Minnesota;   Baylor Health Care System;   Medical University of South Carolina;   University of Chicago;   University of Pittsburgh Medical Center;   Dartmouth-Hitchcock Medical Center;   Johns Hopkins University;   Children's Hospital Medical Center, Cincinnati;   Ohio State University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
    NCT03539601
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Crisaborole ointment, 2%;   Drug: Hydrocortisone butyrate cream, 0.1%;   Drug: Pimecrolimus cream, 1%;   Drug: Crisaborole Vehicle
    Sponsor:   Pfizer
    Recruiting
  • Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
    NCT04146363
    Condition:   Atopic Dermatitis
    Interventions:   Biological: Lebrikizumab;   Other: Placebo
    Sponsor:   Dermira, Inc.
    Recruiting
  • The Global cVAD Study
    NCT04136392
    Condition:   Cardiovascular Diseases
    Intervention:   Device: ABIOMED, Inc. hemodynamic support devices
    Sponsors:   Abiomed Inc.;   Beth Israel Deaconess Medical Center;   Yale University
    Recruiting
  • Pulmonary Hypertension Association Registry
    NCT04071327
    Conditions:   Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Pulmonary Hypertension
    Intervention:  
    Sponsors:   Pulmonary Hypertension Association, Inc.;   University of Washington, the Collaborative Health Studies Coordinating Center
    Recruiting
  • Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.
    NCT04036435
    Condition:   Psoriasis
    Intervention:   Drug: BMS-986165
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)
    NCT03593395
    Condition:   Sickle Cell Disease
    Interventions:   Other: Peer Mentoring [PM];   Other: Structured Education Based Transition Program STE
    Sponsors:   Ifeyinwa (Ify) Osunkwo MD MPH;   Patient-Centered Outcomes Research Institute
    Recruiting
  • MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
    NCT03962543
    Conditions:   Plexiform Neurofibroma;   Neurofibromatosis Type 1 (NF1)
    Intervention:   Drug: PD-0325901 oral capsule
    Sponsor:   SpringWorks Therapeutics, Inc.
    Recruiting
  • Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
    NCT03903822
    Condition:   Atopic Dermatitis
    Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
    Sponsor:   Pfizer
    Recruiting
  • Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
    NCT03824405
    Condition:   Atopic Dermatitis
    Interventions:   Drug: BTX 1204;   Drug: Vehicle
    Sponsor:   Botanix Pharmaceuticals
    Recruiting
  • A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
    NCT03635983
    Condition:   Melanoma
    Interventions:   Biological: NKTR-214;   Biological: Nivolumab
    Sponsors:   Bristol-Myers Squibb;   Nektar Therapeutics
    Recruiting
  • A Long Term Safety Study of BCX7353 in Hereditary Angioedema
    NCT03472040
    Conditions:   Hereditary Angioedema;   HAE;   Prophylaxis
    Intervention:   Drug: BCX7353
    Sponsor:   BioCryst Pharmaceuticals
    Recruiting
  • Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
    NCT03435796
    Condition:   Neoplasms
    Intervention:   Genetic: Gene-modified (GM) T cell therapy
    Sponsor:   Celgene
    Recruiting
  • Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
    NCT03428945
    Condition:   Type1 Diabetes Mellitus
    Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
    Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Juvenile Diabetes Research Foundation
    Recruiting
  • Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
    NCT03428646
    Condition:   Dermatitis, Atopic
    Intervention:   Drug: Dupilumab
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
    NCT03339297
    Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
    Interventions:   Drug: Defibrotide;   Drug: Standard of Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
    NCT03289273
    Condition:   Liver Neoplasms
    Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
    Sponsor:   Bayer
    Recruiting
  • A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
    NCT03181932
    Conditions:   MRSA;   Cystic Fibrosis
    Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
    Sponsor:   Savara Inc.
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
    NCT03104413
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
    Sponsor:   AbbVie
    Recruiting
  • Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
    NCT03052517
    Condition:   Asthma
    Interventions:   Drug: QAW039 Dose 1;   Drug: QAW039 Dose 2;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
    NCT02720744
    Conditions:   Excessive Daytime Sleepiness;   Cataplexy;   Narcolepsy
    Interventions:   Drug: Sodium Oxybate;   Drug: Placebo
    Sponsor:   Avadel
    Recruiting
  • Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
    NCT02717507
    Condition:   Cancer Survivor
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
    NCT02435992
    Condition:   Ulcerative Colitis
    Interventions:   Drug: RPC1063;   Drug: Placebo
    Sponsor:   Celgene
    Recruiting
  • OPsumit USers Registry
    NCT02126943
    Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
    NCT01442194
    Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • International Collaborative Gaucher Group (ICGG) Gaucher Registry
    NCT00358943
    Conditions:   Gaucher Disease;   Cerebroside Lipidosis Syndrome;   Glucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting
  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
    NCT00271180
    Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
    Intervention:   Device: Device
    Sponsor:   Medtronic
    Recruiting
  • Pompe Disease Registry
    NCT00231400
    Conditions:   Glycogen Storage Disease Type II;   Pompe Disease
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting
  • Mucopolysaccharidosis I (MPS I) Registry
    NCT00144794
    Condition:   Mucopolysaccharidosis I (MPS I)
    Intervention:  
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC